Seeking Alpha

anomaly1

anomaly1
Send Message
View as an RSS Feed
View anomaly1's Comments BY TICKER:
Latest  |  Highest rated
  • Noranda Aluminum - Buyout Candidate [View article]
    buy the stock and lose 100% possible in BK. AVOID.
    May 27, 2015. 10:00 PM | Likes Like |Link to Comment
  • Tableau: Blistering Growth, Fanciful Valuation [View article]
    Have established short in DATA as it traded below 112 today
    May 26, 2015. 01:52 PM | Likes Like |Link to Comment
  • CorMedix's (CRMD) CEO Randy Milby on Q1 2015 Results - Earnings Call Transcript [View article]
    Where are the $CRMD bulls now?

    All the hypesters are gone.
    May 26, 2015. 11:17 AM | Likes Like |Link to Comment
  • King Digital Entertainment's (KING) CEO Riccardo Zacconi Discusses Q1 2015 Results - Earnings Call Transcript [View article]
    "FX impact, what we saw over the past quarter was approximately a 9% decrease in the non-U.S. currencies. Those impact about half of our business on the gross bookings side. So if you are going to look at that from a numeric perspective, I would say about $20 million to $25 million impact to the Q2 guidance as we look forward to Q2."

    FX impact is reversing. Expect this impact to be lessened easily by end of year.
    May 15, 2015. 02:51 AM | 2 Likes Like |Link to Comment
  • King Digital Entertainment's (KING) CEO Riccardo Zacconi Discusses Q1 2015 Results - Earnings Call Transcript [View article]
    "Having said that, we expect to see the impact of not launching a new title in Q1 this year."
    May 15, 2015. 02:17 AM | 1 Like Like |Link to Comment
  • Should You Buy Qorvo Going Into Earnings? [View article]
    QRVO squeeze time
    May 7, 2015. 08:37 AM | 1 Like Like |Link to Comment
  • Vale Continues To Fall On Unstable Environment [View article]
    It is a buy all you can. Price overshot to lows. Now co. is cutting back on production by 30M tons.
    Iron ore price will jump as the big 3 cutback production.
    May 1, 2015. 08:08 AM | 3 Likes Like |Link to Comment
  • Vale Grows Furiously - Will The Trend Continue? [View article]
    how stock pricing works... oversold when negatives are out

    now $VALE is underpriced because it was oversold.

    recovery has just begun. Iron ore demand is back on the uptrend, i.e. reversal.

    Temporary profit taking by people who use %s as an excuse to sell will miss out for the run to the mid teens.
    Apr 28, 2015. 08:14 PM | 2 Likes Like |Link to Comment
  • Alpha Natural Resources Sees Light At The End Of The Tunnel [View article]
    why wouldn't you prefer BTU vs ANR?
    Apr 28, 2015. 07:05 PM | Likes Like |Link to Comment
  • Advaxis immunotherapy candidate 100% successful in anal cancer trial [View news story]
    Many of articles I've read on Advaxis have been written by employees of Advaxis.

    My colleagues in cancer immunotherapy find that many of the stated results of trials are worded improperly.
    Mar 24, 2015. 10:45 AM | Likes Like |Link to Comment
  • CorMedix: Up Too Far Too Fast [View article]
    I statement: Neutrolin is NOT approved.

    Not prudent to assume 100% of the valuation when Neutrolin approval is more than 2 years away.

    Plenty of time to buy the stock. Why get in now vs. later? Shares are being sold next from upcoming exercised warrants.
    Mar 20, 2015. 12:45 AM | Likes Like |Link to Comment
  • CorMedix: Up Too Far Too Fast [View article]
    Their track record for shorts, checked their page stats, are very good.

    The article has facts. I don't care for the horse comments.
    Mar 20, 2015. 12:42 AM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    The longs that are pumping want to make money.

    The shares being sold via warrant exercise in the upcoming weeks want to be sold for as high a price as possible, so its obvious they want to keep stock afloat by convincing holders not to sell beforehand.

    Street Sweeper states they have a short position. They are pro shorts so i would assume they know what they are talking about. Check out the performance of their previous shorts. Looks like they do well at shorting.
    Mar 19, 2015. 10:58 PM | 1 Like Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    more

    "Noting, “We will not receive any proceeds from the sale of shares registered under this prospectus,” CorMedix held the earnings call and filed a registration statement clearing shareholders to sell $19 million worth of stock.

    So, 75 stockholders can soon sell 2.45 million dilutive shares on the public market."
    Mar 19, 2015. 10:22 PM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    Watch out below....

    http://bit.ly/1ynRNXw

    "Dr. Lindsay Rosenwald, who directly and indirectly loaned ~$604,000 to CorMedix in 2009 apparently is running with the herd, too. Altogether he’s selling more than 138,000 shares.

    TheStreetSweeper first warned shareholders in July 2013 about one of biotech’s best known horse traders, Dr. Rosenwald. We told about the curly-haired Dr. Rosenwald’s interesting alliances and his bizarre whipworm egg therapeutic company, Coronado Biosciences (CNDO then ~$8, now ~$3).

    Dr. Rosenwald co-founded and financed Interneuron, maker of an anti-obesity drug. The drug was related to the “fen” in the “fen-phen” drug cocktail eventually beset by safety concerns that led to more than 3,000 lawsuits and withdrawal from the U.S. market in 1997.

    Other biotech companies he founded or heavily supported have also dumped investors head-first.

    These include:

    Avax Technologies: deregistered in March 2009, now worth under a penny.

    Biocryst: once traded at $34, now $10.

    Genta: poster child for toxic financial deals, U.S. Food and Drug Administration rejections and horrible clinical trials. FDA ultimately ruled against Genta’s cancer drugs and the company lost a crucial $480 million deal with Aventis. Genta filed for chapter 7 bankruptcy.

    Neose Technologies: filed a certificate of dissolution in March 2009. Under management’s final plan, liquidating distribution approved at $0.0121.

    Ventrus Biosciences: founded and supported by Rosenwald, traded over $21 in 2011, now trading for ~$1."
    Mar 19, 2015. 10:20 PM | Likes Like |Link to Comment
COMMENTS STATS
921 Comments
555 Likes